linjc16/ctgov huggingface dataset:
Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial

Study Overview
=================
Brief Summary
-----------------
to assess whether cessation of 12 months DAPT regimen containing Ticagrelor results in a hyperreactive phase of platelet function

Detailed Description
-----------------
the study will be composed of a cohort of patients , who completed 12 months of DAPT with Ticagrelor (standard recommended dose for ACS - 90 mg BID), did not experience any clinical or adverse event during this time period and are about to discontinue Ticagrelor. We intend to measure the platelet reactivity for each patient on 4 time points - prior to cessation of Ticagrelor (i.e. while still on DAPT) and 1,4 and 12 weeks post discontinuation of therapy. There will not be a control group.

Official Title
-----------------
Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial

Conditions
-----------------
Dual Antiplatelet Therapy, Platelet Reactivity

Intervention / Treatment
-----------------
* Other: Platelet reactivity testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age>18 underwent coronary stent implantation due to ACS completed 12 month of DAPT regimen containing Ticagrelor at standard dose (90 mg BID) Exclusion Criteria: any ischemic or bleeding events while under Ticagrelor any other Ticagrelor associated adverse effects planned for continuation of Ticagrelor for more than 12months post stenting according to the judgment of the attending physician. Unable to make informed consent .

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| DAPT patients<br>Patients planned for cessation of DAPT regimen containing Ticagrelor after 12 months of treatment following coronary stent implantation . the platelet reactivity will be assessed 1 week prior to cessation of DAPT and than at 1,3,and 12 weeks post DAPT cessation. | Other: Platelet reactivity testing<br>* assessment of platelet aggregation using the VerifyNow purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) platelet function assay (Accumetrics, San Diego, California)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| platelet reactivity |  | from 1 week prior to 12 weeks post DAPT cessation |
Pleurostrain: Interest of Strain Ultrasound in the Diagnosis of Pneumothorax

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to investigate whether the use of strain ultrasound can improve the lung ultrasound accuracy for the diagnosis of pneumothorax, particularly for inexperienced physicians.

Detailed Description
-----------------
Prospective multi-centre diagnostic study based on the post-interpretation of recorded ultrasound loops as part of standard patient management.

Official Title
-----------------
Interest of Strain Ultrasound in the Diagnosis of Pneumothorax: Prospective Multicenter Observational Study

Conditions
-----------------
Pneumothorax

Intervention / Treatment
-----------------
* Diagnostic Test: Strain ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 17 years old Management in an investigative centre Presenting a suspicion of pneumothorax Having had a pulmonary ultrasound scan Having had a CT scan within 2 hours after or before the pulmonary ultrasound Exclusion Criteria: Pregnant or breastfeeding women Persons not covered by a social security scheme Persons deprived of their liberty The patient is participating in another study The patient is in an exclusion period determined by a previous study The patient is under the protection of justice, guardianship or curatorship Patient refuses to participate It is impossible to give informed information about The patient does not read French fluently Patient with any known pulmonary pathology pre-existing prior to the hospitalization episode Patient with a lung condition other than pneumothorax on a scanner

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pneumothorax<br>Pneumothorax | Diagnostic Test: Strain ultrasound<br>* Post-interpretation of recorded ultrasound loops<br>|
| Normal<br>Normal lung | Diagnostic Test: Strain ultrasound<br>* Post-interpretation of recorded ultrasound loops<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pneumothorax diagnosis by an inexperienced physician in lung ultrasound | The main endpoint will be a binary qualitative value: diagnosis of pneumothorax (yes/no) judged by inexperienced physicians performing pleural strain. | May 1, 2021 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pont-of-Care Ultrasound
Microvolt T-wave Alternans in Cardiac Surgery Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to measure MTWA in the patients undergoing cardiac surgery and to investigate the relation between MTWA and adverse clinical outcomes.

Official Title
-----------------
Microvolt T-wave Alternans in Cardiac Surgery Patients

Conditions
-----------------
Postoperative Complications, Electrocardiogram: Electrical Alternans

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients underwent cardiac surgery including coronary artery bypass graft surgery with or without cardiopulmonary bypass, cardiac valve surgery, cardiac mass excision, thoracic aorta surgery, etc. Exclusion Criteria: unavailability of the recording equipment

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cardiac surgery<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| in hospital mortality | in hospital death | up to 3 months(during hospital stay) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative complication | The secondary end points were myocardial infarction, ventricular tachycardia, atrial fibrillation, cardiogenic shock, stroke, coma, renal failure, respiratory failure, and length of stay in intensive care unit (ICU) and hospital. | up to 3 months(during hospital stay) |
Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

Study Overview
=================
Brief Summary
-----------------
Open, non-randomized, radiolabelled, single centre study designed to characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg [14C]-radiolabelled AZD2281 (KU-0059436) in patients with advanced or metastatic solid tumours.

Official Title
-----------------
Open, Non-Randomized, Single Centre Phase I Study to Assess the Metabolism, Excretion and Pharmacokinetics of a Single Oral 100 mg Dose of [14C]-AZD2281 (KU-0059436) in Patients With Advanced or Metastatic Solid Tumours Refractory to Standard Treatments

Conditions
-----------------
Neoplasm Metastasis

Intervention / Treatment
-----------------
* Drug: AZD2281


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed advanced or metastatic tumour, refractory to standard therapies Exclusion Criteria: Anti-cancer therapy including chemotherapy, radiotherapy (excluding palliative radiotherapy), endocrine therapy, immunotherapy or use of other investigational agents within 4 weeks prior to study entry. Patients may continue the use of LHRH agonists for cancer, bisphosphonates for bone disease and corticosteroids provided the dose is stable before and during the study. Females will be able to continue to take hormone replacement therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: AZD2281|100mg Oral Dose|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg [14C]-radiolabelled AZD2281 (KU-0059436) in patients with advanced or metastatic solid tumours, assessed by blood, urine and faecal sampling |  | Various timepoints | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the safety and tolerability of AZD2281 (KU-0059436) by assessment of adverse events, laboratory findings and vital signs. |  |  | 
| To provide plasma and excreta samples for future studies to investigate metabolite profiles and characterize human metabolites |  |  | 
| To make a preliminary evaluation of clinical response as measured by objective tumour response rates at various timepoints. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Poly(ADP ribose) polymerases, Metastatic Solid Tumours
The Role of Incretins in Bone Remodeling in Humans

Study Overview
=================
Brief Summary
-----------------
The role of incretins (GIP and GLP-1) on cells and bone tissue has been shown in cellular and animal studies. In humans, the role of these hormones is mainly studied in the pathophysiology of diabetes, their effect on bone is unknown. The serum incretin concentration is low and increases rapidly after a meal. This increase is brief, incretins being rapidly degraded by dipeptidylpeptidase 4 (DPP-4). The dosage of these hormones is complex and the basal normal serum concentrations and after feeding in healthy subjects are unknown. Before any study on the effect of incretins on bone remodeling in humans, it is necessary to establish physiological concentrations of incretins in healthy subjects. The aim of this study is to estimate physiological concentrations of incretins in healthy subject.

Official Title
-----------------
INcrétines et REModelage OSseux

Conditions
-----------------
Healthy, Incretins, Osteoporosis, Bone Remodeling

Intervention / Treatment
-----------------
* Other: blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy women and men Exclusion Criteria: known osteoporosis osteoporotic fracture tobacco alcohol : > 2 glasses/day type 1 and type 2 diabetes BMI < 19kg/m² or > 30kg/m² heart failure, kidney failure cancer bariatric surgery graft cirrhosis use in the past year : bisphosphonate, denosumab, raloxifene, teriparatide, oral or IV glucocorticoid during 3 months or more

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: blood sample|we perform blood sample in healthy subject before and after a meal to measure incretins concentration|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incretins concentrations before and after a meal in healthy subjects |  | 2 years |
Prevalence of Chronic Abdominal Pain in Migraneurs

Study Overview
=================
Brief Summary
-----------------
To collect data on the prevalence of Chronic Abdominal Pain in Migraneurs in Germany

Official Title
-----------------
Prevalence of Chronic Abdominal Pain in Migraneurs

Conditions
-----------------
Migraine, IBD

Intervention / Treatment
-----------------
* Other: observation study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: chronic abdominal pain migraine Exclusion Criteria: not able to sign written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: observation study|observation study|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual analog scale (VAS) for pain | Number of migraneurs with chronic abdominal pain based on the VAS | observational, through study completion, an average of 1 year |
Sickness Absence Versus Physical, Mental, and Job-related Factors in Patients With Chronic Pulmonary Disease

Study Overview
=================
Brief Summary
-----------------
People with chronic respiratory disease have shortened work life, their disease is associated with greater work disability and they are at greater risk of being unemployed. Lower employment rates and higher sickness absence is expensive for the community and leads to financial as well as social consequences for the individual. There is a lack of data on factors that can predict sickness absence and disability in patients with pulmonary disease. We therefore want to study a group of people with COPD and asthma referred to our clinic. The study will investigate relationships between sickness absence and exercise capacity, job-related factors, disease severity, self-efficacy, health related quality of life and subjective health complaints.

Official Title
-----------------
Relationships Between Sickness Absence and Physical, Mental, and Job-related Factors in Patients With Chronic Pulmonary Disease

Conditions
-----------------
Chronic Obstructive Pulmonary Disease, Asthma

Intervention / Treatment
-----------------
* Other: Vocational pulmonary rehabilitation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: chronic pulmonary disease employed periods of sickness absence in the year prior to admittance Exclusion Criteria: lack of ability to complete the rehabilitation program

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Pulmonary vocational rehabilitation<br> | Other: Vocational pulmonary rehabilitation<br>* Multidisciplinary pulmonary rehabilitation with emphasis on vocational issues<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects absent from work more than 10 days 4 weeks prior to follow-up | The subjects are interviewed after 12 months. Number of days absent from work during 4 weeks prior to the interview are recorded. | 12 months |
Multi Detector-Row Computed Tomography (MDCT) Calcium Score of Heart Transplanted Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine if calcium score can be used as a predictor of coronary artery disease in heart transplanted patients, as it is used in non-transplanted persons.

Detailed Description
-----------------
Several studies have shown that a negative calcium score is a strong independent negative predictor of coronary artery disease (CAD). CAD in heart transplants (HTx) differs from CAD lesions in native hearts. The aim of this study is to see if there is a similar relation between coronary artery calcium and CAD in transplanted hearts as in native hearts.

Official Title
-----------------
MDCT Calcium Score of Heart Transplanted Patients

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Procedure: MDCT calcium score


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Heart transplanted patient Aged 18 or above. Exclusion Criteria: Pregnancy Atrial fibrillation Severe heart failure New York Heart Association (NYHA) class IV Severe pulmonary disease making the patient unable to hold his/her breath for more than 10 seconds.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: MDCT calcium score|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Calcium score |  | at the date of examination | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Coronary stenoses found on coronary angiography |  | at the date of examination | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary artery disease, Coronary calcium score, Cardiac transplantation, Coronary calcium score in heart transplanted patients, Coronary artery disease in heart transplanted patients
Role of Greyscale and Power Doppler Sonography in Therapy Monitoring in Early Rheumatoid Arthritis (RA)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the role of musculoskeletal ultrasound and power Doppler in early therapy monitoring of rheumatoid arthritis patients.

Official Title
-----------------
Therapy Monitoring in Early Rheumatoid Arthritis: The Role of Greyscale and Power Doppler Sonography A Prospective Study Of 20 Egyptian Rheumatoid Arthritis Patients

Conditions
-----------------
Rheumatoid Arthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults: age at disease onset >18 years and < 50 years Disease duration < 3 month Fulfilling ARA criteria for classification of RA DMARD naive Exclusion Criteria: Age at diagnosis < 18 years Disease duration > 3 month Previous use of DMARDS Previous use of biologics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Effect of Fatigue on the Clinical Performance

Study Overview
=================
Brief Summary
-----------------
The primary aim of this randomized controlled trial is to examine the effect of fatigue on clinical performance in a simulated obstetric emergency. This scenario was chosen because it is a common clinical situation faced by anesthesia providers on call and therefore likely to occur when a provider is fatigued. Secondary outcomes will include the evaluation of other factors that worsen fatigue related decrement in performance including age, years of training/practice and clinical load prior to study participation.

Official Title
-----------------
The Effect of Fatigue on the Clinical Performance of Experienced Physicians: A Simulation Study

Conditions
-----------------
Fatigue

Intervention / Treatment
-----------------
* Other: Fatigued
* Other: Rested


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All attending anesthesiologists taking overnight call at Evanston Hospital will be eligible participants. Exclusion Criteria: Resident physician or trainee, physician not taking overnight in house call.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Rested<br>Subjects will perform the scenario, once during a normal workday (rested) | Other: Rested<br> <br> |
| Active Comparator: Fatigued<br>Subjects will perform the scenario after working a 12-24 hour overnight shift (fatigued). | Other: Fatigued<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical performance Score | Performance score on Stat c-section rating scale based on video rating by 2 raters | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stanford Sleepiness Scale | SSS scores in rested and fatigue arms | 24months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Human Performance, Clinical Performance